Gene Therapy Explained: What It Is, How It Works, and Where Medicine Is Headed

For most of medical history, treating a genetic disease meant managing the symptoms for life. Yet gene therapy suggests that some diseases can be addressed at their source by altering genetic fabrication. Though the field is still young, it has moved from theory to a real part of clinical medicine.

What Is Gene Therapy?

Essentially, gene therapy refers to treatments that work by adding, silencing or editing genetic material inside a patient’s cells. This broad definition encompasses several strategies. 

Some therapies deliver a working copy of a gene to compensate for one that’s missing or faulty. Others use newer gene-editing tools, such as CRISPR, to directly correct or disable a specific segment of DNA. A related category, cell therapy, modifies a patient’s own cells outside the body before returning them. The two fields overlap sufficiently that regulators often group them together as “cell and gene therapies.”

It’s worth separating this from more familiar biotech, like vaccines or antibody drugs. Those treatments interact with the body’s existing systems. Gene therapy is meant to change what the cells themselves are instructed to do, ideally with effects that last for years, and in some cases, for life. 

Getting a New Gene Where It Needs to Go

The central engineering problem in gene therapy is primarily about delivering the therapy to the right cells without triggering a dangerous immune reaction or causing unintended damage elsewhere in the genome.

The most common delivery method uses viruses that have been modified so they can no longer cause disease, but can still slip genetic material into a cell. Adeno-associated viruses, usually shortened to AAV, are a popular choice because they tend to provoke a relatively mild immune response and can target specific tissues, such as the liver, the retina or muscle. Lentiviruses are also used, particularly in therapies that modify blood-forming stem cells outside the body.

Gene-editing approaches work differently. Instead of just inserting a new gene, tools like CRISPR-Cas9 act more like molecular scissors, cutting DNA at a precise location so a cell’s own repair machinery disables or rewrites a target sequence. The technology is even used to kill cancer cells. 

This is also how Casgevy, approved in late 2023 for sickle cell disease, works. It edits a gene involved in red blood cell production rather than adding a new one. Newer delivery methods, including lipid nanoparticles similar to those used in mRNA vaccines, are also being tested to deliver editing tools into the body without using a virus at all.

Therapies are also generally described as either in vivo, meaning the treatment is delivered directly into the patient’s body, or ex vivo, meaning cells are removed and modified in a lab before being infused back into the patient. CAR T-cell cancer therapies are a well-known example of an ex vivo approach.

From Research Idea to Approved Treatment

Gene therapy has had a rocky path to clinical use. Early trials in the late 1990s and 2000s encountered serious safety problems, including cases in which viral vectors triggered fatal immune reactions. Those setbacks slowed the field for years and pushed researchers toward safer delivery systems.

The turning point came roughly a decade ago. Luxturna, approved in 2017, treats an inherited form of vision loss and was among the first gene therapies cleared for use in the U.S. Zolgensma followed in 2019 for spinal muscular atrophy, a severe and often fatal disease in infants. 

Since then, the approval pace has picked up noticeably. Treatments like Hemgenix for hemophilia B, Zynteglo for beta thalassemia, Elevidys for Duchenne muscular dystrophy and the CRISPR-based Casgevy and Lyfgenia for sickle cell disease have all reached patients within the past few years. 

The Reality of Cost and Access

While the science is genuinely impressive, it comes with real limitations that are easy to gloss over in headlines. Several approved gene therapies cost well over a million dollars per patient, a price driven by small patient populations, complex manufacturing and the cost of years of clinical trials. Insurers and health systems are still working out how to pay for treatments that are extremely expensive up front but potentially curative, rather than ongoing.

There are also scientific unknowns. Researchers don’t yet have decades of follow-up data on most gene therapies. Questions about how long-term effects and gene activity are still being answered. Additionally, gene-editing tools raise a separate concern. There is a risk of off-target edits, in which the editing tool alters DNA where it wasn’t intended to. Safety testing has improved considerably, but it remains an active area of research rather than a fully solved problem.

Where the Field Is Headed

Most approved gene therapies so far target rare, single-gene disorders. This makes sense, since these are diseases with a clear genetic cause and a well-defined fix. Advancements are likely to involve in vivo gene editing, where the editing tool is delivered directly into the body. This eliminates the need to remove cells. Early trials for conditions such as a rare form of amyloidosis have already shown promise. The evidence has unveiled that lasting genetic changes can be achieved without surgery or a lab-based cell-processing step.

In the long term, researchers are also looking at whether these tools can be adapted for more common conditions. These include certain forms of heart disease, where a single edit could have lasting effects rather than requiring daily medication. That shift, from rare disease to widespread chronic conditions, is probably the development that will determine how big a role gene therapy ultimately plays in everyday medicine.